Katherine A. High

Katherine A. High
Born
NationalityAmerican
Alma materHarvard College, University of North Carolina School of Medicine
Known forGene Therapy
Childrenthree, including Sarah Steele
Scientific career
FieldsHematology
InstitutionsUniversity of Pennsylvania, Spark Therapeutics
Academic advisorsEdward J. Benz Jr.

Katherine A. High is an American doctor-scientist who is an emeritus professor at the Perelman School of Medicine at the University of Pennsylvania. She was the co-founder, president, and chief scientific officer of Spark Therapeutics and currently serves as President of Therapeutics at AskBio. She has worked in the area of gene therapy, performing both basic research and clinical investigations. She has been recognized for her distinguished contributions to the field, having designed, sponsored, and conducted the first clinical trial of an adeno-associated viral vector (AAV) gene therapy injected into the skeletal muscle (1999), the first trial of AAV gene therapy introduced into the liver (2001), and the first trial in the US of an AAV gene therapy injected into the subretinal space (2007).